InteliSpark client theMednet has been awarded a Direct-to-Phase II SBIR contract from the National Cancer Institute (NCI) for the development of cancer prevention and treatment clinical trials tools for recruitment and retention of diverse populations. https://lnkd.in/eqmHEFC6
InteliSpark, LLC
资金募集机构
Ithaca，New York 2,473 位关注者
Experts at obtaining non-dilutive funding for start-ups through SBIR, STTR, and other federal funding programs.
关于我们
InteliSpark, LLC is a hands-on business development consulting firm specializing in securing non-dilutive funding for start-ups through the Small Business Innovative Research (SBIR), Small Business Technology Transfer (STTR), and other government research funding programs. We work with start-ups, universities, venture capital firms and economic development programs to match small innovative companies and technologies with funding opportunities. Using our proven track record of creating winning SBIR/STTR proposals, we turn those opportunities into realities. In 2002, InteliSpark founder Kirk Macolini started our predecessor company, Centurion Technology, to help the innovative companies compete for SBIR/STTR awards. InteliSpark was formed in 2016 to broaden the mission of providing assistance to include universities, venture capital firms, and economic development programs
- 网站
-
https://www.InteliSpark.com
InteliSpark, LLC的外部链接
- 所属行业
- 资金募集机构
- 规模
- 11-50 人
- 总部
- Ithaca，New York
- 类型
- 私人持股
- 创立
- 2016
- 领域
- SBIR/STTR proposals、non-dilutive funding、proposal development和commercialization of University IP
地点
-
主要
获取路线
950 Danby Rd
US，New York，Ithaca，14850
InteliSpark, LLC员工
-
Keiko Seino
Grants Manager at InteliSpark, LLC
-
Kirk Macolini
President at InteliSpark, LLC, SBIR & STTR Expert (>$400,000,000 in non-dilutive funding secured)
-
Samantha Tinsley, Ph.D.
STTR/SBIR Funding Strategy Consultant | Cancer Biology PhD
-
Soumya Mukherjee, PhD
SBIR/STTR Startup Funding Consultant
动态
-
InteliSpark Client EnFuego Therapeutics has advanced to Phase II in their National Cancer Institute (NCI) STTR/SBIR Fast-Track grant on Ligand-Directed KRAS G12V Mutant-Specific Therapeutics #SBIR #AUTM #STTR #cancer #therapeitics #startupfunding #nih https://lnkd.in/epnEeYW9
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
reporter.nih.gov
-
InteliSpark client Renerva, LLC has been awarded a National Institute of Neurological Disorders and Stroke (NINDS) Phase I SBIR Grant for Restoration of Neuromuscular Function Following Critical Nerve Gap Injuries. #nerveinjuries #lifescience #nih #SBIR #startupfunding https://lnkd.in/eRs3JucY
Restoration of Neuromuscular Function Following Critical Nerve Gap Injuries
reporter.nih.gov
-
InteliSpark client Salient has been awarded a NOAA: National Oceanic & Atmospheric Administration Phase II SBIR award for Machine learning and ocean variables for improved predictions of water availability in the U.S #SBIR #MachineLearning #ai #climatetech #startupfunding https://lnkd.in/eYJ3B4Kf
NOAA invests $11M in small businesses to advance innovative technologies - Technology Partnerships Office
techpartnerships.noaa.gov
-
InteliSpark client Neuronasal (https://neuronasal.com/) has been awarded a National Institute on Aging (NIA) Phase I STTR grant entitled Circumventing the pharmacokinetic/pharmacodynamic limitations of antioxidant therapy for Parkinson's Disease by nose to brain delivery of N-acetylcysteine #Parkinsons #nih #sttr #startupfunding https://lnkd.in/ejkgEBTv
antioxidant therapy for Parkinson's Disease by nose to brain delivery of N-acetylcysteine
reporter.nih.gov
-
The number of SBIR project pitches that the National Science Foundation (NSF) is receiving has dramatically increased. Currently NSF is receiving almost 80 project pitches for every Phase I proposal that it funds. A trend that looks to continue moving forward. #SBIR #STTR #NSF
-
-
InteliSpark client Shasqi has been awarded a National Cancer Institute (NCI) Direct to Phase II grant for Antigen-targeted activation of Topo1 inhibitors via click chemistry #nci #nih #sbir #startupfunding #cancer #drugdelivery https://lnkd.in/esyg7KGa
Antigen-targeted activation of Topo1 inhibitors via click chemistry
reporter.nih.gov
-
InteliSpark client Zymtronix has been awarded a National Institute of General Medical Sciences (NIGMS) Phase II SBIR grant for Scaling-up flow processes for the chemoenzymatic synthesis of a sialylated glycan #sbir #glycobiology #startupfunding #NIH https://lnkd.in/ezVtq9zk
Scaling-up flow processes for the chemoenzymatic synthesis of a sialylated glycan
reporter.nih.gov
-
InteliSpark client Rejuvenation Technologies Inc. has been awarded a National Institute of General Medical Sciences (NIGMS) Phase I SBIR grant for Clinically-useful vehicles for in vivo delivery of mRNA to stem and progenitor cells. #nih #SBIR #grantfunding #startupfunding #mRNA https://lnkd.in/e5ZCjVE9
Clinically-useful vehicles for in vivo delivery of mRNA to stem and progenitor cells.
reporter.nih.gov
-
InteliSpark client CytoAgents, Inc has been awarded a National Cancer Institute (NCI) Direct to Phase II SBIR grant entitled TO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients #cancerresearch #nih #SBIR #startupfundingh https://lnkd.in/ekBSxT38
CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients
reporter.nih.gov